Cycloferon in local immunotherapy in patients with virus-associated rhinitis

Close metadata

MATERIALS AND METHODS

A comparative analysis of the treatment of 72 patients with allergic rhinitis, divided into groups: I (main, n=21), which included immunocompromised patients who received sublingual allergen-specific immunotherapy with antipollin and inhaled immunotherapy with cycloferon (every other day, a course of 10 procedures, the total dose of Cycloferon per course is 1250 mg); II (comparison, n=22) — immunocompromised patients who received monotherapy with antipollinum and III (control, n=29) — patients with allergic rhinitis without signs of immunocompromise, who also received antipollinum. The effectiveness of therapy was assessed by the quality of life (RQLQ questionnaire), the severity of nasal symptoms (the patient’s self-observation diary) and the need for drugs after a course of intranasal immunotherapy.

RESULTS

The inclusion of cycloferon in the treatment of immunocompromised patients with allergic rhinitis increased its effectiveness — the severity of nasal symptoms decreased: in terms of sneezing, a decrease of 53.5 times versus 1.82 — in the control, «nasal congestion» — 6.3 times versus 2.6 — in the control, «itching in the nose» — 4.9 and 4.2 times, respectively (p<0.05). The changes had a positive effect on the total indicator of the quality of life of patients — an increase of 6.2 times (by 83.7%) (p>0.05) and significantly reduced the need for cromones (18 times, versus 10.3 — in the group comparison), inhaled corticosteroids (10.4 times versus 8 times in the comparison group, and in decongestans — 8.1 times versus 6.1 — in the comparison group (p>0.05)).

CONCLUSIONS

The combined use of local immunotherapy with cycloferon and sublingual allergen-specific immunotherapy with antipollinum in immunocompromised patients with allergic rhinitis is the first-line method of choice that statistically significantly changes the quality of life of patients.

Keywords:

cycloferon

local immunotherapy

immunocompromised patient

allergic rhinitis

sublingual immunotherapy

antipollinum

quality of life

Authors:

Tataurschikova N.S.

RUDN University

Received:

15.10.2020

Accepted:

15.12.2020

List of references:

Karpova EP, Baratashvili AD. Phenotypic classification of rhinitis and basic principles of therapy. RMZh. 2019;8:33-36. (In Russ.).
Kakli HA, Riley TD. Allergic Rhinitis Review Prim Care. 2016;43(3):465-475. https://doi.org/10.1016/j.pop.2016.04.009
Sangidorzh B, Tataurshhikova NS, Ronzhina AN. Local immunotherapy in patients with virus-associated allergic rhinitis. Prakticheskaja medicina. 2017;10(111):99-103. (In Russ.).
Watts AM, Cripps AW, West HP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294. https://doi.org/10.3389/fphar.2019.00294
Vlajkov A, Vicheva D, Dimov P, Stojanov V. Assessment of the quality of life of patients with allergic rhinitis. Rossijskaja rinologija. 2016;1(26):38-42. (In Russ.). https://doi.org/10.17116/rosrino201624138-42
Allergic rhinitis. Clinical guidelines RAAKI, 2018. M. 2018;11. (In Russ.).
Pashkova TM, Pashinina OA, Popova LP, Kartashova OL, Kovalenko AL. The effect of cycloferon on antibiotic resistance of Staphylococcus aureus. Jeksperimental’naja i klinicheskaja farmakologija. 2017;80:8:27-30. (In Russ.). https://doi.org/10.30906/0869-2092-2017-80-8-27-30
Kovalenko AL, Grigorjan SS, Isaeva EI, Vetrova EN. Antiviral effect of cycloferon in influenza a (H3N2) cell cultures. Jeksperimental’naja i klinicheskaja farmakologija. 2019;82:5:33-36. (In Russ.). https://doi.org/10.30906/0869-2092-2019-82-5-36-39
Tataurshhikova NS. Cycloferon in clinical allergology. SPb.: Taktik-Studio; 2009. (In Russ.).
Vahitov HM, Pikuza OI, Vahitova LF, Zakirova AM, Rizvanova FF. Interferon inducers in the prevention and treatment of respiratory infections in children. Rossijskij vestnik perinatologii i pediatrii. 2019;64:(3)103-108. (In Russ.).

Close metadata